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E-mail address: ksemba@waseda.jp (K. Semba).Gene ampliﬁcation is a major genetic alteration in human cancers. Amplicons, ampliﬁed genomic
regions, are believed to contain ‘‘driver’’ genes responsible for tumorigenesis. However, the signiﬁ-
cance of co-ampliﬁed genes has not been extensively studied. We have established an integrated
analysis system of amplicons using retrovirus-mediated gene transfer coupled with a human full-
length cDNA set. Applying this system to 17q12–21 amplicon observed in breast cancer, we identi-
ﬁed GRB7 as a context-dependent oncogene, which modulates the ERBB2 signaling pathway through
enhanced phosphorylation of ERBB2 and Akt. Our work provides an insight into the biological sig-
niﬁcance of gene ampliﬁcation in human cancers.
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DNA ampliﬁcation is a major genetic alteration contributing to
oncogenesis [1]. Historically, some proto-oncogenes identiﬁed as
cellular counterparts of retroviral oncogenes were found to be
ampliﬁed in human cancers. Thus, it is thought that unidentiﬁed
proto-oncogenes exist in ampliﬁed genomic regions called ‘‘ampli-
cons’’, and ampliﬁed proto-oncogenes express large amount of pro-
teins, leading to oncogenesis. We previously constructed gene
expression maps of chromosomes in human breast cancer cell lineschemical Societies. Published by E
d protein 7; ERBB2, v-erb-b2
TV, mouse mammary tumor
d protein kinase; MEK, MAPK
ular signal-regulated kinase;and extracted six novel amplicons [2]. Nevertheless, it is not easy
to identify such proto-oncogenes because ampliﬁcation events of-
ten include multiple genes, and because more information is re-
quired, including precise mapping of ampliﬁed regions in
multiple cancers and deduced function of each gene. A few ﬁndings
provided the signiﬁcance of co-ampliﬁed genes except speciﬁc
oncogenes in the amplicon in terms of cancer cell phenotypes. In
non-small-cell lung cancer, for instance, co-ampliﬁcation of TTF-1
and NKX2–8 in the 14q13.3 amplicon renders cancer cells resis-
tance to cisplatin [3]. However, the biological signiﬁcance of co-
ampliﬁcation for oncogenesis has not been validated extensively.
In this study, we focused on the functions of co-ampliﬁed genes
localized in the 17q12–21 amplicon containing ERBB2 as a driver
gene [4]. The ERBB2 amplicon is observed in 25% of breast cancers,
and also in ovarian, gastric and esophagus cancers [5]. Clinicopatho-
logical data indicate that ERBB2 expression is a poor prognostic factor
[6]. Furthermore, an active ErbB2mutant called neu oncogene causes
cellular transformation of NIH3T3 cells [7] and breast cancer in trans-lsevier B.V. All rights reserved.
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moter [8]. These results support the idea that ERBB2 functions as a
driver gene for oncogenesis when mutated or overexpressed.
To examine the function of co-ampliﬁed genes in the ERBB2 ampli-
con, we tested these genes for enhancement of ERBB2 cellular trans-
forming activity. For this purpose, we introduced a human wild-
type (WT) ERBB2 expression vector into NIH3T3 cells and established
‘‘non-transformed’’ cells moderately expressing ERBB2 under the
CMVpromoter. Then, human full-length cDNAs of co-ampliﬁed genes
were retrovirally introduced into ERBB2-expressingNIH3T3 cells, and
the transformingactivitywas assessed by focus formation assays. Our
screening systemensuresmultiple expressionof completeproteins in
cells, thereby enabling the examination of combinations of co-ampli-
ﬁed genes in the ERBB2 amplicon.
Here,weshowGRB7gene,which is locatedabout10 kbfromERBB2
locus and is frequently co-ampliﬁed with ERBB2, caused efﬁcient
transformation of NIH3T3 in concert with ERBB2; this ERBB2-depen-
dent transformingactivitywasspeciﬁc forGRB7amongtheGRB7fam-
ily proteins. This was consistent with the observation that
phosphorylation of ERBB2 was increased when GRB7 was expressed,
but not other GRB7 family proteins. Importantly, phosphorylation of
Akt at Thr308 and Ser473 was upregulated when both ERBB2 and
GRB7wereexpressed.We further examined the transformingactivity
ofaseriesofGRB7mutants,andshowedthataBPSregiondeletionmu-
tant of GRB7 is a potent activator of ERBB2 and Akt, while the trans-
forming activities of other domain deletion mutants are severely
impaired.
Our model of collaborative transformation by ERBB2 and GRB7
proposes that GRB7 is a cytoplasmic activator and adaptor of
ERBB2, enhances ERBB2 phosphorylation, and connects ERBB2 to
Akt. Our analysis also highlights the biological signiﬁcance of gene
ampliﬁcation in terms of simultaneous overexpression of a driver
gene and ‘‘supporter’’ genes.focus assay
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Fig. 1. ERBB2-dependent transforming activity of GRB7. (A) A scheme of oncogene-scre
ERBB2 were infected with GRB7, and cultured for 17 days (upper). Scale bar, 500 lm. Cel
used as a control. Volume of virus stock used in this experiment was 125 ll.2. Materials and methods
2.1. DNA constructs and antibodies
To construct an ERBB2 expression vector, human ERBB2 (Ref-
Seq: NM_004448) cDNA was inserted in pQCXIN retroviral vector
(Clontech, Mountain View, CA). Human full-length cDNAs were ob-
tained from the human proteome expression resource (HuPEX) [9],
and cloned into pMXs retroviral vector [10] using the Gateway
Cloning system (Life Technologies, Carlsbad, CA) with or without
N-terminal FLAG epitope tag. Venus ﬂuorescent protein [11] was
used as a control. Primary antibodies were as follows: anti-a-tubu-
lin DM1A (Sigma, St. Louis, MO), anti-FLAGM2 (Sigma), anti-ERBB2
(SV2-61c, Nichirei Bioscience, Japan), anti-HER2/ErbB2 (#2242,
Cell Signaling Technology (CST), Danvers, MA), anti-Phospho-
HER2/ErbB2 (Tyr877) (CST#2241), anti-Phospho-HER2/ErbB2
(Tyr1221/1222) (CST#2243), anti-Phospho-HER2/ErbB2 (Tyr1248)
(CST#2247), anti-Erk1/2 (CST#4695), anti-Phospho-Erk1/2
(#4370), anti-Phospho-MEK1/2 (CST#9154), anti-Akt (pan)
(#4691), anti-Phospho-Akt (Thr308) (CST#2965), anti-Phospho-
Akt (Ser473) (CST#4060), and anti-Phosphotyrosine 4G10 (Milli-
pore, Billerica, MA). Secondary antibodies for western blotting
were purchased from GE Healthcare (Piscataway, NJ).
2.2. Cell culture
NIH3T3 cells were obtained from RIKEN Cell Bank (Tsukuba, Ja-
pan) and cultured in DMEM supplemented with 5% heat-inacti-
vated calf serum, 100 U/ml penicillin, and 100 lg/ml
streptomycin at 37 C and 5% CO2. 3T3-ERBB2 cells were estab-
lished by retroviral infection of pQCXIN-ERBB2 and selection with
1 mg/ml G418. Plat-E packaging cells were obtained from T. Kitam-
ura (Institute of Medical Science, University of Tokyo), and culturedVenus GRB7
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Fig. 2. ERBB2-dependent Akt activation and transformation by GRB7. (A) Focus formation assays with GRB proteins and ERBB2. 3T3-ERBB2 were infected with each GRB7
family protein or GRB2, and cultured for 20 days. Scale bar, 1 mm. (B) Phosphorylation status of ERBB2 in GRB7 family-expressing cells. ERBB2 immunoprecipitates prepared
from GRB7 family-expressing cells were analyzed by anti-phosphotyrosine antibody. (C) Effect of expression of ERBB2 with GRB proteins. Phosphorylation status of ERBB2
and components of MAPK and Akt pathways were analyzed by phosphorylation-speciﬁc antibodies. Distinct amount of virus stock was used as follows: Venus (30 ll), GRB2
(480 ll), GRB7 (90 ll), GRB10 (360 ll), GRB14 (480 ll) for control NIH3T3, and Venus (20 ll), GRB2 (360 ll), GRB7 (60 ll), GRB10 (240 ll), GRB14 (360 ll) for 3T3-ERBB2.
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and streptomycin, as above.
2.3. Retroviral packaging
Plat-E cells were seeded into 6-cm culture dishes at a density of
1.0 106 and transfected with 4 lg of retroviral plasmids mixed with
10 ll of Lipofectamine 2000 reagent (Life Technologies). One day after
transfection, the culture supernatant was replaced with NIH3T3 media.
The following day, culture supernatant was harvested and centrifuged
to remove cell debris, then stored at 80 C as virus stock.
2.4. Focus formation assays
NIH3T3 cells were seeded into 12-well culture plates at a concen-
tration of 5.0 104 and the following day, the cells were infected
with 1 ml of appropriately diluted virus stock containing 8 lg/ml
polybrene. To carefully adjust the expression level of each protein,
distinct amount of virus stock were used. The next day, cells were
seeded into 10-cm culture dishes and cultured for several days.
Then, infected cells (1.0 105) were seeded again into 10-cm culture
dishes and maintained for 2–3 weeks with medium change every
2 days. Cell foci were stained with 0.05% crystal violet and counted.
2.5. Recovery of cDNAs from NIH3T3 transformants
Transformed NIH3T3 cells were picked from each focus and cul-
tured to isolate genomic DNA. cDNAs inserted into genome wereampliﬁed with a pair of primers for pMX vector (pMXs-s1811:
GACGGCATCGCAGCTTGGATA and pMXs-AS3200: TTATCGTCGAC-
CACTGTGCTG) and KOD FX polymerase (Toyobo, Japan) for 30 cy-
cles of 98 C for 10 s, 55 C for 15 s, and 68 C for 2 min, and
subcloned into pBluescript SK() (Agilent Technologies, Santa
Clara, CA). Two hundred and thirteen informative sequences were
obtained by an Applied Biosystems 3130 genetic analyzer (Life
Technologies).
2.6. Constructs of GRB7 mutants
To construct expression vectors for GRB7 mutants, pMXs-FLAG-
GRB7 plasmid was ampliﬁed with an appropriate set of primers,
then the PCR product was self-ligated to obtain a mutated plasmid
[12].
2.7. Western blotting and immunoprecipitation
Cells were rinsed in ice-cold PBS and lysed in RIPA buffer
(10 mM Tris–HCl, pH8.0, 150 mM NaCl, 1 mM EDTA, 1% NP-40,
0.1% sodium deoxycholate, 0.1% SDS, 1 mM Na3VO4, 10 mM NaF,
17.5 mM b-glycerophosphate, and 1 mM PMSF) for analysis of total
cell lysates, or Triton lysis buffer (50 mM Tris–HCl, pH 8.0, 135 mM
NaCl, 1 mM EDTA, 1% TritonX-100, 10% glycerol, 1 mM Na3VO4,
10 mM NaF, and 1 mM PMSF) for immunoprecipitation. Protein
amounts used in Figs. 2B and 4 were 225 and 500 lg, respectively.
Protein lysates were incubated with 2 lg anti-ERBB2 (SV2-61c) for
1 h at 4 C, and immunoprecipitated with 20 ll of protein A-Se-
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Fig. 3. Transforming activity of GRB7 domain deletion and point mutants. (A) Structures of the GRB7 mutants used in the experiments. (B) Focus formation assays with GRB7
mutants. 3T3-ERBB2 were infected with WT or mutant GRB7, and then cultured for 16 days (upper). Scale bar, 1 mm. Cells were ﬁxed and stained with crystal violet (lower).
(C) Expression level of ERBB2 andWT or mutant GRB7. Distinct amount of virus stock was used as follows: GRB7WT (250 ll), del-PR (500 ll), del-RA (500 ll), del-PH (250 ll),
del-BPS (250 ll), del-SH2 (500 ll), R458 K (500 ll), F511A (250 ll), Venus (250 ll).
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boiled for 5 min in SDS–PAGE sample buffer, and separated with
7.5% or 10% acrylamide gels. Proteins were transferred onto PVDF
membranes (Immobilon-P, Millipore), rinsed in TBS (20 mM Tris–
HCl (pH 7.5), and 150 mM NaCl) and incubated in blocking bufferIP: ERBB2
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Fig. 4. Effect of GRB7 mutants on Akt phosphorylation. Lysates from 3T3-ERBB2,
WT and mutant GRB7 were immunoblotted using anti-phospho-Akt-speciﬁc
antibodies. ERBB2 immunoprecipitates were also analyzed to assess total phos-
phorylation by anti-phosphotyrosine antibody. Amounts of virus stock used are
shown in Fig. 3.(TBS containing 3–5% non-fat dry milk or 5% bovine serum albu-
min) for 1 h at RT or overnight at 4 C. The membranes were incu-
bated for 1 h at RT or overnight at 4 C with primary antibodies.
Proteins were labeled using HRP-conjugated secondary antibodies
diluted at 1:2000 for 1 h at RT, then visualized by the enhanced
chemiluminescence method using Immobilon Western reagent
(Millipore).
3. Results
To screen for ERBB2-dependent transforming genes, we estab-
lished NIH3T3 derivative (3T3-ERBB2) moderately expressing hu-
man WT ERBB2 under the control of CMV promoter. Mixtures of
full-length human cDNA clones corresponding to the 52 genes (Ta-
ble 1) within the ERBB2 amplicon were cloned into pMX retroviral
vectors, and then retroviral expression vectors were introduced
into Plat-E packaging cells. 3T3-ERBB2 was infected with the resul-
tant retrovirus mixture. Two to three weeks after infection, 30 foci
were identiﬁed, whereas no foci were observed for 3T3-ERBB2
without retroviral infection. Each focus was isolated, expanded,
and lysed for preparation of genomic DNA to analyze integrated
cDNAs (Fig. 1A, Supplementary Table 1).
To test the transforming activity of most frequently recovered
cDNAs, 12 representative cDNAs (Table 1) were individually intro-
duced into 3T3-ERBB2. As a result, only GRB7 (RefSeq:
NM_001030002) reproducibly induced foci. Transformed cells
were smaller than normal cells and piled up on one another. The
Table 1
Fifty-two genes analyzed in this study.
Gene symbol RefSeq ID Frequency
C17orf78 NM_173625 9
TADA2A NM_001166105 5
DUSP14 NM_007026 9
SYNRG NM_001163546 0
DDX52 NM_007010 2
HNF1B NM_000458 4
MRPL45 NM_032351 0
SOCS7 NM_014598 1
SRCIN1 NM_025248 0
MLLT6 NM_005937 0
PCGF2 NM_007144 5
PSMB3 NM_002795 3
PIP4K2B NM_003559 0
CWC25 NM_017748 2
RPL23 NM_000978 6
LASP1 NM_006148 0
PLXDC1 NM_020405 4
CACNB1 NM_000723 3
RPL19 NM_000981 5
FBXL20 NM_032875 0
MED1 NM_004774 0
PPP1R1B NM_032192 2
STARD3 NM_001165937 11
TCAP NM_003673 21
PNMT NM_002686 11
PGAP3 NM_033419 16
ERBB2 NM_004448 0
C17orf37 NM_032339 7
GRB7 NM_001030002 11
IKZF3 NM_012481 2
GSDMB NM_001165959 0
ORMDL3 NM_139280 5
GSDMA NM_178171 0
PSMD3 NM_002809 5
CSF3 NM_172219 10
MED24 NM_014815 1
THRA NM_001190919 7
NR1D1 NM_021724 0
MSL1 NM_001012241 2
RAPGEFL1 NM_016339 2
WIPF2 NM_133264 0
CDC6 NM_001254 0
RARA NM_000964 9
LOC100131821 AK123052 4
IGFBP4 NM_001552 6
TNS4 NM_032865 13
CCR7 NM_001838 2
SMARCE1 NM_003079 0
KRT24 NM_019016 2
KRT25 NM_181534 3
KRT28 NM_181535 3
TMEM99 NM_145274 0
Genes are aligned in order of chromosome location. Frequency of genes appeared in
30 foci are shown. 12 cDNAs individually introduced into 3T3-ERBB2 are shown in
bold.
Table 2
Focus formation assay with GRB proteins and ERBB2.
Number of foci after 20 days (10 cm-culture dish)
Venus GRB2 GRB7 GRB10 GRB14
Experiment 1
Control 0 0 0 0 0
ERBB2 0 2 6 0 0
Experiment 2
Control 1 0 0 0 0
ERBB2 0 5 13 0 0
Distinct amount of virus stock were used as follows: Venus (30 ll), GRB2 (480 ll),
GRB7 (90 ll), GRB10 (360 ll), GRB14 (480 ll) for control NIH3T3, and Venus
(20 ll), GRB2 (360 ll), GRB7 (60 ll), GRB10 (240 ll), GRB14 (360 ll) for 3T3-ERBB2.
Expression level of each protein was analyzed in Fig. 2C.
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that of H-Ras(G12V)-transformed foci (data not shown). GRB7 in-
duced transformation of 3T3-ERBB2, but not of parental NIH3T3
(Fig. 1B), indicating that transformation of NIH3T3 by GRB7 is
dependent on ERBB2 expression.
GRB7 is one of the GRB7 family proteins, which are known to
bind receptor tyrosine kinases and mediate signal to downstream
effectors [13]. We carried out focus formation assays to determine
whether ERBB2-dependent transforming activity is only limited to
GRB7 or conserved in all GRB7 family proteins. We also tested
GRB2, a well-known adaptor protein with distinct structure from
GRB7, in addition to GRB7 family proteins. No foci were observed
when each GRB protein (GRB2, GRB7, GRB10 and GRB14) was ex-
pressed individually in NIH3T3 cells; however, with the expression
of ERBB2, a number of foci were reproducibly observed when
either GRB7 or GRB2 was expressed (Fig. 2A, Table 2). This result
indicates that ERBB2-dependent transforming activity was speciﬁc
to GRB7 among the GRB7 family proteins.
To assess whether the transforming activity of GRB7 is based on
activation of ERBB2, we evaluated the phosphorylation status of
ERBB2 by expression of GRB7 compared with other GRB7 family
proteins. To analyze total phosphorylation of ERBB2, whole cell ly-
sates of 3T3-ERBB2 expressing one of the GRB7 family proteins
were subjected to immunoprecipitation with an ERBB2 antibody.
Then, the phosphorylation status of ERBB2 was analyzed using
phosphotyrosine-speciﬁc antibody 4G10. As shown in Fig. 2B,
ERBB2 phosphorylation was considerably upregulated in GRB7-
expressing cells. GRB14 also increased ERBB2 phosphorylation;
however, GRB10 had no effect. To determine which tyrosine resi-
dues of ERBB2 are phosphorylated when GRB7 is expressed, whole
cell lysates of 3T3-ERBB2 expressing one of the GRB proteins were
immunoblotted using a series of phospho-speciﬁc antibodies
against ERBB2. As shown in Fig. 2C, phosphorylation of Tyr1221/
1222 and Tyr1248 was upregulated in GRB7-expressing cells,
while that of a Src phosphorylation site, Tyr877, was unaltered,
suggesting that GRB7 promotes or retains ERBB2 autophosphoryla-
tion in particular. We therefore evaluated the effects of GRB7 and
ERBB2 on signaling pathways that are frequently deregulated in
cancer, that is, MAPK and PI3K-Akt pathways. We analyzed activa-
tion of components of these pathways by activation state-speciﬁc
antibodies. These data showed that compared with other GRB pro-
teins, co-expression of ERBB2 and GRB7 had no effect on the phos-
phorylation status of MEK or Erk. In contrast to components of the
MAPK pathway, phosphorylation of Akt at Thr308 and Ser473 was
marginally upregulated by expression of either ERBB2 or GRB7, but
greatly upregulated when both proteins were expressed (Fig. 2C).
These results suggest that cooperative transformation of ERBB2
and GRB7 may require Akt activation.
To dissect functional domains required for transforming activity
of GRB7, we constructed ﬁve corresponding deletion mutants, PR
(proline-rich), RA (Ras-associating), PH (Pleckstrin homology),
BPS (between PH and SH2), and SH2 (Src-homology 2), and two
point mutants for SH2 domain (Fig. 3A). R458K has a defect in
the phosphotyrosine binding capacity of its SH2 domain, while
F511A has a dimerization defect [14]. We assessed their transform-
ing activity on 3T3-ERBB2 by focus formation assays. As shown in
Fig. 3B and C, four GRB7 mutants, del-PR, del-RA, del-PH, and del-
SH2, were defective in the transforming activity of 3T3-ERBB2
cells. R458K was also impaired in transforming activity, and the
number of foci was reduced. In contrast, F511A retained compara-
ble transforming activity with WT GRB7. However, del-BPS pro-
moted foci formation, although its transforming activity was still
dependent on ERBB2 (data not shown). Taken together, all four do-
mains are required for ERBB2-dependent transforming activity of
GRB7, except for its BPS region.
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pseudo substrate of the insulin and IGF1 receptors, and directly
inhibits their catalytic activities [15]. Therefore, we hypothesized
that BPS region of GRB7 downregulates ERBB2 kinase activity in
spite of its activator function of ERBB2. To address this hypothesis,
we compared WT and mutant GRB7 in terms of their effect on
ERBB2 and Akt phosphorylation. As shown in Fig. 4, ERBB2 phos-
phorylation was increased by deletion of the BPS region. Moreover,
Akt phosphorylation was concomitantly increased. These results
indicate that the BPS region of GRB7 potentially represses ERBB2
activity in a similar manner to the inhibition of insulin and IGF1
receptors by GRB7 family proteins. Of the other transformation-
deﬁcient mutants, del-RA had no effect on ERBB2 and Akt phos-
phorylation, while del-PR, del-PH, and del-SH2 increased ERBB2
phosphorylation as well as WT but had no effect on Akt phosphor-
ylation. Two point mutants with transforming activity retained
ERBB2 and Akt phosphorylation. These results indicate that the
transformed phenotype correlated with Akt activation status.
4. Discussion
Gene ampliﬁcation is one of the major genetic alterations in
cancer, which leads to overexpression of several genes. Amplicons
recurrently observed in human cancers are likely to be positively
selected owing to their contribution to oncogenesis, and indeed,
amplicons have been shown to include cancer driver genes. But
information on the signiﬁcance of other co-ampliﬁed genes has
been limited.
Accumulating clinical evidence indicate that ERBB2 is a driver
gene of several types of cancers. In fact, transforming activity of
ERBB2 depends on its conformational status and expression level.
An ErbB2 mutant observed in rat neuroblastoma called neu onco-
gene, which tends to form dimers [16], has transforming activity
[7]. Furthermore, strong expression of WT ERBB2 driven by retro-
viral LTR showed transforming activity [17]. In contrast, moderate
expression of WT ERBB2 driven by SV40 promoter did not cause
transformation [17]. We hypothesized that some of the genes in
the 17q12–21 amplicon may cooperate with ERBB2 to cause
tumorigenesis in the case ERBB2 expression is relatively low. To
test this hypothesis, we assessed the transforming activity of all
genes in the amplicon under the moderate expression of ERBB2.
Our 3T3-ERBB2 cells formed neither foci nor colonies, enabling
us to identify GRB7 as a gene that enhances the transforming activ-
ity of ERBB2.
In the screening of 52 genes in the amplicon, we detected inte-
gration of GRB7 in 11 out of 30 foci analyzed (Table 1, Supplemen-
tary Table 1). This result suggested the existence of oncogenes
other than GRB7 in the amplicon. In fact, we identiﬁed another no-
vel transforming gene in the amplicon with the same strategy
using NMuMG-ERBB2, which we established by introducing ERBB2
expression vector into NMuMG, a mouse mammary epithelial cell
line (A.M., manuscript in preparation). Some foci did not contain
either of them (Supplementary Table 1). One possibility is that
combination of multiple genes, which do not have independent
transforming activity, causes transformation. Alternatively, recov-
ering integrated cDNAs from genomic DNA of transformants may
be biased in PCR ampliﬁcation and cloning and thus some of the
cDNAs might have been missed. Nevertheless, the fact that the
remaining 50 genes (except for GRB7 and the novel transforming
gene) in the ERBB2 amplicon did not induce any foci strongly sug-
gests that either of the two genes is necessary for cellular
transformation.
GRB7 has a unique feature in the activation of ERBB2. ERBB2-
dependent transforming activity is observed only in GRB7 among
the GRB7 family proteins (Fig. 2A). Previous studies demonstratedGRB7 binds to ERBB family receptors, especially ERBB2 and ERBB3,
through its SH2 domain [18]. Increased ERBB2 phosphorylation
was observed in response to expression of GRB7, suggesting that
this binding speciﬁcity contributes to its effect on ERBB2. Also in
our transformation model, Akt phosphorylation correlated with
the transformation phenotype of NIH3T3 (Figs. 3B and 4). Akt is
deregulated in a wide spectrum of human cancers, such as breast,
ovarian and thyroid cancers [19], and transforming activity of its
truncated form in NIH3T3 has been reported [20]. Our results sug-
gest activation of ERBB2-GRB7-Akt axis is sufﬁcient for cellular
transformation.
Our study with GRB7 mutants provides insights into the
mechanism by which GRB7 activates ERBB2 and Akt. GRB7 fam-
ily proteins consist of an RA domain, PH domain, BPS region and
SH2 domain [13]. Among them, deletion of the BPS region in
GRB7 increases ERBB2 phosphorylation and enhances transfor-
mation, suggesting two possibilities: ﬁrst, the BPS region of
GRB7 may inhibit ERBB2 kinase activities in a similar way that
the BPS regions of GRB10 and GRB14 interfere with IGF1 recep-
tors as pseudo-substrates [15]. Second, as it was recently shown
that IGF1 receptor and ERBB2 were co-immunoprecipitated in
SK-BR-3 breast cancer cells [21], GRB7 may enhance complex
formation of ERBB2 and IGF1 receptor. If this is the case, lack
of BPS region may facilitate IGF1 receptor to phosphorylate
ERBB2. The RA domain, deﬁned by sequence homology between
the Ras effectors, is also involved in the phosphorylation of both
ERBB2 and Akt. However, the molecular function of RA domain
still remains to be elucidated.
Previous studies showed that GRB7 was required for SK-BR-3
cell proliferation and ERK1/2 and Akt phosphorylation [22,23].
Conversely, overexpression of GRB7 and ERBB2 in MCF-7 breast
cancer cells enhance ERBB2 and Akt phosphorylation and tumor
xenograft growth [24]. These studies suggested a possible involve-
ment of GRB7 in the neoplastic phenotype of breast cancer cells.
Beyond these studies, we further reveal GRB7 as a unique trans-
forming gene, which does not show transforming activity by itself
but cooperatively transforms NIH3T3 cells with ERBB2. Further-
more, we provide evidence for the signiﬁcance of its BPS and RA
domains in the ERBB2-GRB7-Akt signaling axis for cellular
transformation.
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